ClinicalTrials.Veeva

Menu

A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

A

Akero Therapeutics

Status and phase

Invitation-only
Phase 3

Conditions

NAFLD/MASLD
NASH/MASH

Treatments

Drug: Placebo
Drug: Efruxifermin

Study type

Interventional

Funder types

Industry

Identifiers

NCT06161571
AK-US-001-0107

Details and patient eligibility

About

The aim of this study is to assess the safety and tolerability of EFX compared to placebo in subjects with non-invasively diagnosed NASH/MASH and NAFLD/MASLD.

Enrollment

700 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Main Study Only:

  • Males and non-pregnant, non-lactating females between 18 - 80 (between 19-80 in the Republic of Korea) years of age inclusive, on the day of signing informed consent
  • Previous history or presence of 2 out of 4 components of metabolic syndrome (obesity, dyslipidemia, elevated blood pressure, elevated fasting glucose) or type 2 diabetes
  • Suspected or confirmed diagnosis of NASH/MASH or NAFLD/MASLD or non-invasively diagnosed NASH/MASH or NAFLD/MASLD

Open-Label Rollover

  • Prior participation in the placebo arm of a previous Akero Phase 2 study

Exclusion criteria

  • Other causes of liver disease based on medical history and/or liver histology and/or central laboratory results, including but not limited to: alcoholic liver disease, autoimmune disorders (e.g., primary biliary cholangitis [PBC], primary sclerosing cholangitis [PSC], autoimmune hepatitis), drug induced hepatotoxicity, Wilson disease, clinically significant iron overload, or alpha-1-antitrypsin deficiency
  • Type 1 or unstable Type 2 diabetes

A reduced list of inclusion and exclusion criteria apply to participants in the open-label rollover extension.

Other inclusion and exclusion criteria may apply.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

700 participants in 3 patient groups, including a placebo group

EFX 50 mg
Experimental group
Treatment:
Drug: Efruxifermin
Placebo
Placebo Comparator group
Treatment:
Drug: Placebo
EFX 50 mg (Open-Label Rollover)
Experimental group
Treatment:
Drug: Efruxifermin

Trial contacts and locations

211

Loading...

Central trial contact

Akero Study Director

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems